Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Among authors: algul h. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
Conditional ablation of Notch signaling in pancreatic development.
Nakhai H, Siveke JT, Klein B, Mendoza-Torres L, Mazur PK, Algül H, Radtke F, Strobl L, Zimber-Strobl U, Schmid RM. Nakhai H, et al. Among authors: algul h. Development. 2008 Aug;135(16):2757-65. doi: 10.1242/dev.013722. Epub 2008 Jul 17. Development. 2008. PMID: 18635610 Free article.
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Ettrich TJ, et al. Among authors: algul h. BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y. BMC Cancer. 2018. PMID: 30594153 Free PMC article.
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.
Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. Berger AW, et al. Among authors: algul h. Theranostics. 2019 Feb 12;9(5):1280-1287. doi: 10.7150/thno.29247. eCollection 2019. Theranostics. 2019. PMID: 30867830 Free PMC article.
Changes in pathogen spectrum and antimicrobial resistance development in the time-course of acute necrotizing pancreatitis.
Würstle S, Hapfelmeier A, Wöhrle C, Dichtl K, Lahmer T, Rasch S, Huber W, Weber A, Algül H, Spinner C, Pichler M, Schmid RM, Mayerle J, Schneider J. Würstle S, et al. Among authors: algul h. J Gastroenterol Hepatol. 2019 Dec;34(12):2096-2103. doi: 10.1111/jgh.14748. Epub 2019 Jul 23. J Gastroenterol Hepatol. 2019. PMID: 31157455
147 results